BMS-309403
CAS No. : 300657-03-8

BMS-309403
Cat. No. : CS-6876
M. Wt. : 474.55
Size Stock Price Quantity Add to Cart Quotation Online
5mg In-stock $84.0
10mg In-stock $144.0
25mg In-stock $312.0
50mg Get quote
100mg Get quote
Products are for research use only. Not for human use. We do not sell to patients.

Bulk Inquiry

Collapse
Your information is safe with us. * Required Fields
  Salutation:
  • Dr.
  • Prof.
  • Mr.
  • Ms.
  • Mrs.
  • Miss.
* Country:
  • United States
  • Canada
  • United Kingdom
  • Australia
  • China
  • Germany
  • France
  • Japan
  • Korea South
  • Switzerland
  • ----------------------------------
  • Albania
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Azerbaijan
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Bolivia
  • Bosnia Herzegovina
  • Brazil
  • Bulgaria
  • Cameroon
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Cyprus
  • Czech Republic
  • Denmark
  • Ecuador
  • Egypt
  • Estonia
  • Fiji
  • Finland
  • France
  • Georgia
  • Germany
  • Gibraltar
  • Greece
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Korea South
  • Kuwait
  • Latvia
  • Lebanon
  • Libya
  • Lithuania
  • Luxembourg
  • Macedonia
  • Malaysia
  • Malta
  • Mexico
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Morocco
  • Nepal
  • Netherlands
  • New Zealand
  • Nigeria
  • Norway
  • Oman
  • Pakistan
  • Paraguay
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Republic of Benin
  • Romania
  • Russia
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sri Lanka
  • Suriname
  • Sweden
  • Switzerland
  • Syria
  • Taiwan
  • Thailand
  • Tunisia
  • Turkey
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • Uruguay
  • Uzbekistan
  • Venezuela
  • Vietnam
  • Zambia
  • Zimbabwe
  • Other Countries
* Applicant name:
* Organization Name:
* Email address:
* Requested quantity:
  • ug
  • g
  • kg
  • t
  • mL
  • L
* Phone number:
  Remarks:
 
Name, 
Organization Name, 
Email address, 
Requested quantity, 
Phone number, 
  • Data Sheet

  • Introduction

  • SDS

  • COA & Spectra

Name: BMS-309403; 
Cat. No. : CS-6876
CAS No. : 300657-03-8
Formula: C31H26N2O3
M. Wt. : 474.55
Solubility: DMSO: ≥62.5 mg/mL

Activity:

BMS-309403 is a potent, selective and cell-permeable inhibitor of fatty acid binding protein 4 (FABP4) with a Ki of less than 2 nM. IC50 & Target: Ki: less than 2 nM (FABP4), 250 nM (FABP3), 350 nM (FABP5)[1] In Vitro: BMS-309403 binds to FABP4 with high affinity and shows over 100-fold selectivity against FABP5 as well as the heart isoform FABP3[1]. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. Treatment with BMS-309403 significantly decreased MCP-1 production from THP-1 macrophages in a dose- and time-dependent manner[2]. BMS-309403 stimulates glucose uptake in C2C12 myotubes in a temporal and dose dependent manner via activation of AMP-activated protein kinase (AMPK) signaling pathway but independent of FABPs[3]. In Vivo: A 6 week treatment with BMS-309403 improves endothelial function, phosphorylated and total eNOS and reduced plasma triglyceride levels but does not affect endothelium-independent relaxations. In cultured human microvascular endothelial cells, lipid-induced A-FABP expression is associated with reduced phosphorylated eNOS and NO production and is reversed by BMS-309403[4]. The extent of atherosclerotic lesion area in the proximal aorta is significantly reduced in the BMS-309403-treated group compared with vehicle-treated controls in both the early and late intervention studies[2].

Protocol:

Animal Administration: BMS-309403 is prepared in 4% Tween 80.[4]Mouse: To determine the effects of pharmacological inhibition of the actions of A-FABP, either the A-FABP inhibitor BMS-309403 (15 mg/kg) or vehicle (4% Tween 80) are administered chronically by daily oral gavage for 6 weeks in ApoE−/− mice (starting at weeks 12 of age). Mice are anaesthetized with a bolus injection of pentobarbitone sodium (230 mg/kg) and their aorta removed and dissected for further analysis[4].

References:

Lin W, et al. BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase. PLoS One. 2012;7(8):e44570.

Lee MY, et al. Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br J Pharmacol. 2011 Apr;162(7):1564-76.

Sulsky R, et al. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg Med Chem Lett. 2007 Jun 15;17(12):3511-5.

Furuhashi M, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 2007 Jun 21;447(7147):959-65.

  • Select Batch :
    • CS-6876 24870
Browsing History
Tags:BMS-309403 supplier,BMS-309403 purchase,BMS-309403 manufacturer,BMS-309403 sigma,BMS-309403 distributor,cost,BMS-309403 buy,BMS-309403 for sale
Please enter your email address
Organization name: Email:

Submit success